J Cancer 2015; 6(11):1179-1186. doi:10.7150/jca.12346 This issue Cite

Review

Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review

Chang-Juan Tao1*, Gang Lin1*, Ya-Ping Xu1✉, Wei-Min Mao2✉

1. Department of Radiation Oncology, Zhejiang Cancer Hospital, No. 38 Guangji Rd., Hangzhou, Zhejiang, 310022, China
2. Department of Thoracic Surgery, Zhejiang Cancer Hospital, No. 38 Guangji Rd., Hangzhou, Zhejiang, 310022, China
*Chang-Juan Tao and Gang Lin contributed equally to this manuscript.

Citation:
Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015; 6(11):1179-1186. doi:10.7150/jca.12346. https://www.jcancer.org/v06p1179.htm
Other styles

File import instruction

Abstract

Currently, the most promising strategy to improve the prognosis of advanced esophageal cancer is neoadjuvant chemoradiation (CRT) followed by surgery. However, patients who achieved pathological complete response can experience more survival benefit. Therefore, it is critical to identify the responders early in the course of treatment. Published data demonstrate that clinic-histopathological factors, molecular biomarkers, and functional imaging are predictive of neoadjuvant therapy. The existing biomarkers, including epidermal growth factor receptors, angiogenetic factors, transcription factors, tumor suppressor genes, cell cycle regulators, nucleotide excision repair pathway, cytokines, and chemotherapy associated genes, need to be validated and novel biomarkers warrant further exploration. Positron emission tomography (PET) is useful for differentiating the responders of neoadjuvant CRT. The most valuable parameters and the time point of performing PET in the course of treatment remains to be elucidated. Furthermore, predictive models incorporating the multiple categories of factors need to be established with a large, prospective, and homogeneous patient cohort in the future. Standardization of staging, biomarker detection method, and image acquisition protocol will be critical for the generalization of this model. Prospective, multi-center controlled trials, which stratified patients according to these predictive factors, will help guide individualized treatment strategies for patients with esophageal cancer.

Keywords: esophageal cancer, neoadjuvant therapy, response, positron emission tomography, biomarkers


Citation styles

APA
Tao, C.J., Lin, G., Xu, Y.P., Mao, W.M. (2015). Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. Journal of Cancer, 6(11), 1179-1186. https://doi.org/10.7150/jca.12346.

ACS
Tao, C.J.; Lin, G.; Xu, Y.P.; Mao, W.M. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J. Cancer 2015, 6 (11), 1179-1186. DOI: 10.7150/jca.12346.

NLM
Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015; 6(11):1179-1186. doi:10.7150/jca.12346. https://www.jcancer.org/v06p1179.htm

CSE
Tao CJ, Lin G, Xu YP, Mao WM. 2015. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer. 6(11):1179-1186.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image